

## Importation of USA – Children’s TYLENOL Oral Suspension due to shortage of pediatric analgesics

Due to the shortage of pediatric **acetaminophen and ibuprofen liquid** in Canada, Health Canada has allowed the importation of Johnson & Johnson Inc. US-labelled **Children’s TYLENOL 160 mg/5 mL Oral Suspension (dye free cherry, grape)**. This medication has been added to Health Canada’s List of Drugs for Exceptional Importation and Sale in Canada.

**Please note: a temporary Product Identification Number has been assigned to Children’s TYLENOL 160 mg/5 mL Oral Suspension (PIN 09858117) effective as of November 28, 2022.**

US-labelled **Children’s TYLENOL 160 mg/5 mL oral suspension**, manufactured by Johnson & Johnson Inc. contains the same concentration, active ingredient, dosage and route of administration as the Canadian-labelled products that were authorized and marketed for sale in Canada; however, the products differ with respect to packaging, volume and inactive ingredients.

The differences between the US-labelled and Canadian authorized product are noted below:

- **differences in inactive ingredients.**
- **larger product size (120 mL)** compared to Canadian product (100 mL), and
- **some differences in warnings and precautions.** For Canadian labelling, please visit [tylenol.ca/products/infants-children/childrens-tylenol-liquid](http://tylenol.ca/products/infants-children/childrens-tylenol-liquid).

Pharmacists and other health care professionals are reminded of the following:

- The US-labelled Children’s TYLENOL 160 mg/5mL Oral Suspension is labelled in English-only. The French-translated text of the US label is available on Johnson and Johnson’s Canada website at the following link: [www.tylenol.ca/sites/tylenol\\_ca/files/children\\_tylenol\\_us\\_product\\_french\\_labelling.pdf](http://www.tylenol.ca/sites/tylenol_ca/files/children_tylenol_us_product_french_labelling.pdf).
- Consult the Canadian Product Monograph for Contraindications, Serious Warnings and Precautions Box and Warnings and Precautions for Children’s TYLENOL 160 mg/5mL on Health Canada’s Product Monograph at [pdf.hres.ca/dpd\\_pm/00062135.PDF](http://pdf.hres.ca/dpd_pm/00062135.PDF).

### Temporary benefit added to the *Alberta Human Services Drug Benefit Supplement (HSDBS)*

Due to the unavailability of acetaminophen liquid, US-Labelled Children’s TYLENOL 160 mg/5 mL Oral Suspension (Temporary PIN 09858117) in dye-free cherry and grape flavour will be considered as temporary benefits for the *HSDBS*.

Temporary PIN	Product description
09858117	Children’s TYLENOL 160 mg/5 mL Oral Suspension (Dye-free cherry and grape flavour)

As of **November 28, 2022**, all claims will be adjudicated to the price of **\$0.1083 per mL**.

Alberta Blue Cross will continue to monitor the availability of the shorted products and potential alternatives, in addition to working with other provinces and territories, manufacturers, and Health Canada to address this shortage and minimize the impact on Albertans.

*continued next page*

*continued from previous page*

## **Additional temporary benefit added to the Alberta Drug Benefit List (ADBL) due to amoxicillin oral suspension shortage**

Due to the ongoing unavailability of amoxicillin oral suspension products, Auro-Amoxicillin 25 mg/ml Oral Suspension (DIN 02458586), Auro-Amoxicillin 50 mg/ml Oral Suspension (DIN 02458594) and Ceftin 125 mg/5 ml Oral Suspension (DIN 02212307) were added as temporary benefits for the ADBL.

Additionally, **M-Amoxi Clav 400 mg & 57 mg/5 mL Powder for Suspension (DIN 02530694)**, manufactured by Mantra Pharmaceuticals will also be considered a temporary benefit for the ADBL.

As of **November 30, 2022**, all claims for M-Amoxi Clav 400 mg & 57 mg/5 mL Powder for Suspension (DIN 02530694) will be adjudicated to the price published in the most recent *Alberta Blue Cross Drug Price List (ABCDPL)* until further notice.

## **Temporary benefit added to the ADBL**

Due to the unavailability of Cyclogyl 1% Ophthalmic Solution (DIN 00252506) manufactured by Alcon Canada Inc. and Cyclopentolate HCL 1% Ophthalmic Solution (DIN 02148382) manufactured by Bausch and Lomb Canada Inc., **Odan-Cyclopentolate 1% Ophthalmic Solution (DIN 00626627)** manufactured by Odan Laboratories Ltd., will be considered a temporary benefit for the ADBL. This grouping was previously added to the Critical Supply Product List on **November 25, 2022**.

As of **November 25, 2022**, all claims for Odan-Cyclopentolate 1% Ophthalmic Solution (DIN 00626627) will be adjudicated to the price published in the most recent ABCDPL until further notice. The ABCDPL is available online at [ab.bluecross.ca/providers/pharmacy-home.php](http://ab.bluecross.ca/providers/pharmacy-home.php).

---

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at

**780-498-8370** (Edmonton and area)

**403-294-4041** (Calgary and area)

**1-800-361-9632** (toll free)

**FAX 780-498-8406** (Edmonton and area)

**FAX 1-877-305-9911** (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct bill drug claims.

Visit [ab.bluecross.ca/providers/pharmacy-home.php](http://ab.bluecross.ca/providers/pharmacy-home.php)

